(-0.01%) 5 478.00 points
(-0.05%) 38 797 points
(0.03%) 19 927 points
(0.25%) $80.53
(1.18%) $2.82
(0.12%) $2 331.90
(-0.33%) $29.30
(-0.22%) $968.80
(0.02%) $0.932
(-0.14%) $10.64
(0.07%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine...
Stats | |
---|---|
Šios dienos apimtis | 111 344 |
Vidutinė apimtis | 428 887 |
Rinkos kapitalizacija | 16.45M |
EPS | $-0.730 ( Q1 | 2024-05-15 ) |
Kita pelno data | ( $-0.530 ) 2024-06-25 |
Last Dividend | $0.250 ( 2012-04-02 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.160 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00500 (0.87%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-07-27 | Dewilde Michel | Buy | 35 000 | Option (Right to Buy Common Shares) |
2023-07-27 | Braga Damian | Buy | 35 000 | Option (Right to Buy Common Shares) |
2023-07-27 | Baxter Jeff | Buy | 70 000 | Option (Right to Buy Common Shares) |
2023-07-27 | Cordeiro Joanne | Buy | 35 000 | Option (Right to Buy Common Shares) |
2023-07-27 | Beattie Nell | Buy | 52 500 | Option (Right to Buy Common Shares) |
INSIDER POWER |
---|
-68.03 |
Last 96 transactions |
Buy: 56 847 323 | Sell: 16 390 901 |
Tūris Koreliacija
VBI Vaccines Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
VBI Vaccines Inc Koreliacija - Valiuta/Žaliavos
VBI Vaccines Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $8.68M |
Bruto pelnas: | $-5.82M (-66.98 %) |
EPS: | $-5.96 |
FY | 2023 |
Pajamos: | $8.68M |
Bruto pelnas: | $-5.82M (-66.98 %) |
EPS: | $-5.96 |
FY | 2022 |
Pajamos: | $1.08M |
Bruto pelnas: | $-10.19M (-942.14 %) |
EPS: | $-16.37 |
FY | 2021 |
Pajamos: | $631 000 |
Bruto pelnas: | $-10.14M (-1 606.81 %) |
EPS: | $-0.270 |
Financial Reports:
No articles found.
VBI Vaccines Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.250 | 2003-12-18 |
Last Dividend | $0.250 | 2012-04-02 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $1.250 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.23 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2003 | $0.250 | 14.60% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0.750 | 16.50% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0.250 | 0.02% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
02 Apr 2012 | $0.250 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
12 Jan 2006 | $0.750 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
18 Dec 2003 | $0.250 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -8.82 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.100 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -10.82 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.340 | 0.800 | -3.30 | -2.64 | [1 - 3] |
quickRatioTTM | 0.185 | 0.800 | -3.62 | -2.90 | [0.8 - 2.5] |
cashRatioTTM | 0.162 | 1.500 | -0.209 | -0.314 | [0.2 - 2] |
debtRatioTTM | 0.672 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -99.66 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -2.04 | 2.00 | -0.681 | -1.362 | [0 - 30] |
freeCashFlowPerShareTTM | -2.06 | 2.00 | -1.031 | -2.06 | [0 - 20] |
debtEquityRatioTTM | -9.28 | -1.500 | -10.00 | 10.00 | [0 - 2.5] |
grossProfitMarginTTM | -0.291 | 1.000 | -8.18 | -8.18 | [0.2 - 0.8] |
operatingProfitMarginTTM | -7.56 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.991 | 1.000 | -6.62 | -6.62 | [0.2 - 2] |
assetTurnoverTTM | 0.125 | 0.800 | -2.50 | -2.00 | [0.5 - 2] |
Total Score | -7.71 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.181 | 1.000 | -0.119 | 0 | [1 - 100] |
returnOnEquityTTM | -10.82 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.06 | 2.00 | -0.688 | -2.06 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -2.04 | 2.00 | -0.681 | -1.362 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.00918 | 1.500 | -3.39 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -5.34 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.79 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
VBI Vaccines Inc
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.